Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | DRD5 | P21918 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063517 | 1.00 | SCN9A (0.35) | SCN9ASIGMAR1DRD3HTR2AHRH1 | |
| SCHEMBL20095802 | 0.80 | SIGMAR1 (0.37) | SCN9ASIGMAR1DRD3HTR2AHRH1 | |
| SCHEMBL20073061 | 0.76 | DRD3 (0.40) | SCN9ASIGMAR1DRD3HTR2AHRH1 | |
| SCHEMBL20072752 | 0.76 | DRD3 (0.35) | SCN9ASIGMAR1DRD3HTR2AHRH1 | |
| SCHEMBL7750182 | 0.71 | IDO1 (0.44) | SIGMAR1IDO1 | |
| SCHEMBL30582768 | 0.70 | MAOB (0.40) | SIGMAR1 | |
| SCHEMBL20063494 | 0.70 | SCN9A (0.40) | SCN9ASIGMAR1 | |
| SCHEMBL13761888 | 0.69 | ADORA2A (0.43) | SIGMAR1 | |
| SCHEMBL13761886 | 0.69 | ADORA2A (0.43) | SIGMAR1 | |
| SCHEMBL12362858 | 0.69 | ADORA2A (0.43) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1478/4885SIGMAR1 459/4885DRD3 1565/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | SCN9A 1478/4885SIGMAR1 459/4885DRD3 1565/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1501/4885SIGMAR1 421/4885DRD3 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.